Novel Targets Podcast

Bringing to Life the Science around Innovative New Drugs, Gene and Cell Therapies

In our latest episode, we’re tackling the thorny issue of therapeutic cancer vaccines.  Nothwithstanding some recent clinical trial failures, there’s still considerable interest in this topic.

Are we on the threshold of a renaissance — a rebirth or awakening in the way we can stimulate the immune system to attract more cytolytic T cells into the tumour?  If not, what needs to be done for this to happen?  If so, what would the new approach(es) look like and how would they differ from what’s gone before?

In this episode we cover several important and related topics, including: the importance of pre-existing Immunity and novel ways to activate the immune system through Cancer Vaccines, Cytokines, Immune Agonists & T cell bispecifics.

The majority of these interviews were recorded at the American Society of Clinical Oncology (ASCO) meeting held in Chicago in June 2017, while others were recorded in Paris or at the Society for Immunotherapy of Cancer (SITC) meeting in National Harbor, MD.

Pre-Existing Immunity

Dr Jérôme Galon

Dr Jérôme Galon

Dr Jérôme Galon (INSERM) is a leading immunologist who works for the French NIH and is co-founder of a diagnostic company, HalioDx.

In this episode of Novel Targets, we take a broad look at a range of new data that has been emerging for the treatment of breast cancer from several recent cancer meetings, and hear from experts who are shaping the future.

This episode is dedicated to the memory of our friend Jody Schoger, one of the founders of the #BCSM breast cancer community.

1. The Metastatic Breast Cancer Project

Not all studies are company sponsored.  Some of them are driven by academics and may involve patients in novel and collaborative ways. Suppose you happen to be a person with metastatic breast cancer… you could have the power to accelerate cancer research in a way that no one else can, as we found in an compelling and candid interview with Dana Farber’s Dr Nikhil Wagle.

Welcome back to Season 3!

In this episode we’re tackling one of the hottest topics in cancer research, why do cancer immunotherapies work in some people, but not in others? Why do they stop working? If we want to obtain long durable responses, then we have to understand and overcome resistance. Some of the meaty topics covered on this episode include:

  • Initial resistance
  • Acquired resistance
  • Immune escape
  • How we may be able to turn non-responders into responders
  • Overcoming immuno-suppression within the tumor microenvironment.

For the Season 2 finale, we’re at the 2016 annual meeting of the American Society of Hematology (ASH). You’ll hear from Dr Alexis Thompson, Dr Brian Druker, Dr Bruce Cheson and Dr John Leonard on some of the latest developments in hematology.

ASH16 Sand Sculpture on Curing Sickle Cell Disease

Sickle Cell Disease – Interview with Dr Alexis Thompson

Dr Alexis Thompson at ASH16Alexis A Thompson MD MPH is Professor Pediatrics (Hematology, Oncology and Stem Cell Transplantation) at the Northwestern University Feinberg School of Medicine in Chicago. A Vice President of the American Society of Hematology (ASH), she will become President in 2018.